Literature DB >> 16399659

Transport and uptake of MTBE and ethanol vapors in a human upper airway model.

Zhe Zhang1, Clement Kleinstreuer, Chong S Kim.   

Abstract

Potential human exposure to vapors of methyl tertiary-butyl ether (MTBE) and ethanol is of increasing concern because these materials are widely used as gasoline additives. In this study we analyzed numerically the transport and deposition of MTBE and ethanol vapors in a model of the human upper respiratory airway, consisting of an oral airway and the first four generations of the tracheobronchial tree. Airflow characteristics and mass transfer processes were analyzed at different inspiratory flow conditions using a three-dimensional computational fluid and particle dynamics method. The deposition data were analyzed in terms of regional deposition fractions (DF = regional uptake/mouth concentration) and deposition enhancement factors (DEF = local DF/average DF) at local micro surface areas. Results show that DF in the entire upper airway model is 21.9%, 12.4%, and 6.9% for MTBE and 67.5%, 51.5%, and 38.5% for ethanol at a flow rate of 15, 30, and 60 L/min, respectively. Of the total DF, 65-70% is deposited in the oral airway for both vapors. Deposition is localized at various sites within the upper airway structure, with a maximum DEF of 1.5 for MTBE and 7.8 for ethanol. Local deposition patterns did not change with inhalation conditions, but DF and the maximum DEF increased with diffusivity, solubility, and the degree of airway wall absorption of vapors, as shown by a greater deposition of ethanol than MTBE. The vapor deposition efficiency as expressed by the dimensionless mass transfer coefficient correlated well with a product of Reynolds (Re) and Schmidt (Sc) numbers. In conclusion, MTBE and ethanol vapors deposit substantially in the upper airway structure with a marked enhancement of dose at local sites, and the deposition dose may be reasonably estimated by a functional relationship with dimensionless fluid flow and diffusion parameters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16399659     DOI: 10.1080/08958370500434172

Source DB:  PubMed          Journal:  Inhal Toxicol        ISSN: 0895-8378            Impact factor:   2.724


  5 in total

1.  Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Effects of Nasal Spray Suspension Particle Size and Properties.

Authors:  Alex Rygg; Michael Hindle; P Worth Longest
Journal:  Pharm Res       Date:  2015-12-21       Impact factor: 4.200

2.  Airway exchange of highly soluble gases.

Authors:  Michael P Hlastala; Frank L Powell; Joseph C Anderson
Journal:  J Appl Physiol (1985)       Date:  2013-01-10

3.  Linking Suspension Nasal Spray Drug Deposition Patterns to Pharmacokinetic Profiles: A Proof-of-Concept Study Using Computational Fluid Dynamics.

Authors:  Alex Rygg; Michael Hindle; P Worth Longest
Journal:  J Pharm Sci       Date:  2016-06       Impact factor: 3.534

4.  Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Development of a CFD Model.

Authors:  Alex Rygg; P Worth Longest
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-01-29       Impact factor: 2.849

5.  Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection.

Authors:  Ana Castro-Balado; Cristina Mondelo-García; Letricia Barbosa-Pereira; Iria Varela-Rey; Ignacio Novo-Veleiro; Néstor Vázquez-Agra; José Ramón Antúnez-López; Enrique José Bandín-Vilar; Raquel Sendón-García; Manuel Busto-Iglesias; Ana Rodríguez-Bernaldo de Quirós; Laura García-Quintanilla; Miguel González-Barcia; Irene Zarra-Ferro; Francisco J Otero-Espinar; David Rey-Bretal; José Ramón Lago-Quinteiro; Luis Valdés-Cuadrado; Carlos Rábade-Castedo; María Carmen Del Río-Garma; Carlos Crespo-Diz; Olga Delgado-Sánchez; Pablo Aguiar; Gema Barbeito-Castiñeiras; María Luisa Pérez Del Molino-Bernal; Rocío Trastoy-Pena; Rossana Passannante; Jordi Llop; Antonio Pose-Reino; Anxo Fernández-Ferreiro
Journal:  Pharmaceutics       Date:  2021-03-05       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.